Gain Therapeutics announced encouraging Phase 1b clinical trial results for rexaceract, its lead drug candidate for Parkinson's disease, showing safety, tolerability, and early signs of efficacy. The FDA has authorized the Investigational New Drug (IND) application, enabling the company to start a Phase 2 study in Q3 2026 across the US, Australia, and Europe. Rexaceract targets disease modification by restoring enzyme function linked to Parkinson's progression, with biomarker improvements supporting its mechanism. The company also promoted key executives and is advancing a second candidate, GT-04686, toward clinical development.
Bitcoin's futures market currently has $48 billion in open interest but only $25 billion in daily trading volume, creating a liquidity mismatch. This means many traders hold large positions but fewer contracts are actively traded, narrowing the marke...
The XRP Ledger released version 3.3.0 featuring Confidential MPT, a privacy amendment that encrypts token balances and transfer amounts while keeping sender and receiver accounts visible. This opt-in feature targets institutional users by addressing ...
Halper Sadeh LLC is investigating whether officers and directors of Monolithic Power Systems, Inc. breached their fiduciary duties to shareholders. Long-term shareholders may seek corporate governance reforms, financial incentives, or other relief. T...
Halper Sadeh LLC is investigating whether certain officers and directors of Zeta Global Holdings Corp. breached their fiduciary duties to shareholders. Long-term Zeta stockholders may seek corporate governance reforms, financial incentives, or other ...
NICE Ltd has earned a buy rating due to its AI-powered growth, global scale, and low financial leverage, even though it faces near-term earnings headwinds. Its CXone platform is benefiting from increased enterprise demand for AI-driven customer engag...
